← Back to Search

Procedure

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

N/A
Waitlist Available
Led By Allison Quick, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how well a light-based treatment works for breast cancer patients with vaginal atrophy. The treatment aims to improve vaginal tissue by using focused light beams to create controlled damage. This could help alleviate symptoms of vaginal atrophy. This method has been used to treat menopausal women with similar symptoms, showing improvement in several small studies.

Eligible Conditions
  • Dyspareunia
  • Vaginal Dryness
  • Cervical Cancer
  • Breast Cancer
  • Painful Intercourse
  • Cancer Survivors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Vaginal Assessment Scale score
Feasibility of laser treatments defined by completion rates and tolerability of treatment
Patient compliance rates
Secondary study objectives
Other symptoms of urogenital atrophy using the Urogenital Distress Inventory
Sexual behavior/function as measured by the Sexual Experiences Scare, Global sexual satisfaction scale, Female Sexual Function Index, and the Female Sexual Distress Scare

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (fractional CO2 laser therapy)Experimental Treatment2 Interventions
Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Laser Therapy
2018
N/A
~520

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
293,244 Total Patients Enrolled
1 Trials studying Dyspareunia
19 Patients Enrolled for Dyspareunia
Allison Quick, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
1 Previous Clinical Trials
19 Total Patients Enrolled
1 Trials studying Dyspareunia
19 Patients Enrolled for Dyspareunia
~8 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top